WO2009103209A1 - 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 - Google Patents
一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 Download PDFInfo
- Publication number
- WO2009103209A1 WO2009103209A1 PCT/CN2008/072647 CN2008072647W WO2009103209A1 WO 2009103209 A1 WO2009103209 A1 WO 2009103209A1 CN 2008072647 W CN2008072647 W CN 2008072647W WO 2009103209 A1 WO2009103209 A1 WO 2009103209A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nafloxacin
- arginine salt
- injection
- pharmaceutical composition
- composition according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- the invention belongs to the field of pharmaceutical preparations and relates to a stable S-(-)-nafloxacin L-arginine salt composition containing S-(-)-nafloxacin L-spermine as an active ingredient An acid salt, and comprising at least one metal chelating agent selected from pharmaceutically acceptable.
- the invention also relates to a process for the preparation of the composition and to its use. Background technique
- Quinolone has now been developed to four generations.
- the first generation is represented by nalidixic acid
- the second generation is represented by pipemidic acid, and it is only effective against Gram-negative bacteria.
- the third generation is the peak period of development of such drugs.
- the fourth-generation quinolone antibiotics further expanded the antibacterial spectrum on the basis of the third-generation broad-spectrum, making it resistant to mycoplasma and chlamydia infection.
- Nafloxacin was developed by Otsuka, Japan, and is a third-generation quinolone antibacterial agent for topical treatment of acne and edema. It was first listed in Sakamoto in 1993 (trade name: Acua t im), listed in Germany in 2004 (trade name: Nadixa), and launched in China in 2005 (trade name: Yiuning, 1% ointment). Currently in pre-clinical studies in the UK and France, and in clinical research in the United States.
- nalfloxacin Due to its absorption and vascular irritation, nalfloxacin can only be used as a topical preparation for dysentery caused by ropionibac ter ium acnes.
- S-(-)-nafloxacin is the main functional isomer, and its antibacterial activity is 64 to 256 times that of the R type isomer and twice that of the racemate.
- S-(-)-Nafloxacin L-arginine salt is prepared by salt formation on the basis of S-(-)-nafloxacin.
- S-(-)-Naflufloxacin and arginine salt further increase the content of the main antibacterial s-(-)-nafloxacin isomer and improve oral bioavailability. Reduced vascular irritation, enabling it to be developed as an oral or injectable preparation.
- the inventors have unexpectedly discovered that the addition of a metal complexing agent to the S-(-)-nafloxacin L-arginine salt formulation can significantly improve S-(-)-nafloxacin L-spermine ammonia.
- the prepared solution is also stable at high temperature sterilization.
- It is an object of the present invention to provide a stable composition comprising S-(-)-nafloxacin L-arginine salt as an active ingredient, and containing at least one selected from pharmacy
- the S-(-)-nafloxacin L-arginine salt including S-(-)-nafloxacin L-arginine salt anhydrate, S-(-)-nafloxacin Star L-arginine monohydrate, S-(-)-nafloxacin L-arginine salt tetrahydrate and other various forms of S-(-)-nafloxacin L-fine
- the salt is measured in the form of an anhydride.
- S-(-)-nafloxacin L-arginine salt can be prepared according to literature methods (J. Med. Chem., 2005, 48, 5232 ⁇ 5242).
- the amount of the active ingredient S-(-)-nafloxacin L-arginine salt per dosage unit is 50 to 1000 mg.
- the metal complexing agent is selected from the group consisting of disodium edetate or calcium disodium edetate.
- the present inventors have found during the research that the S-(-)-nafloxacin L-arginine salt drug solution is liable to change color under illumination conditions without the addition of a metal complexing agent, and the present invention is unstable. It has been further found that the addition of the metal complexing agent disodium edetate or disodium edetate to the formulation can achieve a good effect of stabilizing the product.
- composition may be administered by injection, for example, as an injection, or as a dosage form for further injection into a lyophilized powder for injection.
- concentration of S-(-)-nafloxacin L-arginine salt in the solution of the present invention or before lyophilization needle freeze-drying is from 1 mg to 40 mg/ml, preferably from 2 mg to 30 mg/ Ml.
- the use of disodium edetate in an intravenous preparation causes a decrease in blood calcium. Therefore, it is necessary to pay close attention to and strictly control the amount of disodium edetate in the intravenous administration preparation.
- the range of use of the general drug is 0.01 to 1. 0%, according to which, the weight ratio of the S-(-)-nafloxacin L-arginine salt to the metal complexing agent is 1 in the composition of the present invention. : 0. 1 ⁇ 1: 10.
- the pharmaceutical composition may further comprise other pharmaceutically acceptable conventional excipients for injection or lyophilized powder for injection, in accordance with the general requirements of the formulation.
- These conventional excipients include, but are not limited to, lyophilized excipients, preservatives, stabilizers, pH adjusters, isotonic agents.
- the excipient may be selected from one or more of mannitol, lactose, glucose, sorbitol, sodium chloride, hydrolyzed gelatin, dextran, sucrose, glycine, polyvinylpyrrolidone, etc., preferably mannitol or glucose.
- the preservative may be selected from, but not limited to, one or more of phenol, indophenol, tri-tert-butanol, benzoquinone, and paraben.
- the stabilizer may be selected from, but not limited to, sodium pyrosulfate, sodium benzoate, sodium sulfite, sodium hydrogen hydride, sulphonic acid, vitamin C, tert-butyl p-hydroxyanisole, dibutyl phenol, One or more of propyl gallate, tocopherol, methionine, cysteine hydrochloride, acetylcysteine, ascorbyl palmitate, ethylenediaminetetraacetic acid.
- pH regulators include, but are not limited to, hydrochloric acid, maleic acid, citric acid, alcoholic acid, phosphoric acid, metaphosphoric acid, polymetaphosphoric acid, carbonic acid, sodium hydroxide, potassium hydroxide, sodium citrate, potassium citrate, carbonic acid Sodium hydrogen, potassium bicarbonate, amine carbonate, phosphorus One or more of disodium acid hydrogenate, dipotassium hydrogenate, ethanolamine, diethanolamine, triethanolamine, sodium carbonate, potassium sodium tartrate, potassium tartaric acid.
- the isotonizing agent can be selected from, but not limited to, sodium chloride, dextrose, potassium chloride, sodium lactate, mannitol or sorbitol.
- the amount of S-(-)-nafloxacin L-arginine salt is not particularly limited and may be any dose which is usually used in the injection.
- each preparation unit contains 50 to 1000 mg of the active ingredient.
- Each of the preparation units referred to refers to each of the water needle or the powder needle, and each bottle of the infusion.
- the pharmaceutical composition of the S-(-)-nafloxacin L-arginine salt of the present invention may be in the form of a clear injectable aqueous solution or in the form of a lyophilized powder for injection.
- the lyophilized powder can be directly dissolved in water for injection, 5% dextrose solution or 0.9% sodium chloride to obtain a clear injection solution.
- the S-(-)-nafloxacin L-arginine salt composition of the present invention has the following characteristics: no special solvent is required, stability is good, clinical use is convenient, and irritation is small.
- the S-(-)-nafloxacin L-arginine salt injection or the lyophilized powder for injection of the present invention is suitable for subcutaneous injection, intra-month injection, Jingyueyong injection or Jingyueyong injection. .
- the present invention provides a method for improving the stability of S-(-)-nafloxacin L-arginine salt, comprising complexing (S)-nafloxacin arginine salt with a metal
- the mixture is mixed with an aqueous solution (aqueous solution, aqueous solution of mannitol or an aqueous solution containing any other auxiliary materials), and then mixed with activated carbon and stirred, after passing through a 0.8 ⁇ m ⁇ filter, and then using a 0.22 ⁇ filter. Sterilization, dispensing.
- the method may further comprise the step of freeze-drying the above-mentioned injection solution to form a lyophilized powder needle, wherein the freeze-drying method is a conventional freeze-drying technique for freeze-drying injection in the field of pharmaceuticals, and the person skilled in the art according to the prior art and the textbook The technical teaching in it can be done without creative labor.
- the S-(-)-nafloxacin L-arginine salt composition of the invention is used in the preparation of an antibiotic drug.
- the composition can be used to treat Gram-positive Various diseases caused by bacteria and negative bacteria, including sepsis, urinary tract infections, respiratory infections.
- the present invention is described in the following detailed description of the preferred embodiments of the invention, and it is understood that the invention is not limited to the specific embodiments. detailed description
- Pre-freezing The temperature of the product drops to -45 °C, and it can be sublimated and dried after 3 hours of heat preservation; Sublimation drying: The daily drying temperature is controlled below -12 °C;
- Re-drying The maximum temperature in the re-drying stage is controlled at 35 °C, and the weight loss of drying should meet the requirements. After the drying is finished, the rubber plug in the box is pressed, the aluminum cover is released from the box, and the finished product is packaged after inspection.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
一种稳定的 S- (-) -那氟沙星 L-精氨酸盐组合物、 其制备方法及用途 技术领域
本发明属药物制剂领域, 涉及一种稳定的 S- (-) -那氟沙星 L-精 氨酸盐组合物, 含有作为活性成分的 S- (-) -那氟沙星 L-精氨酸盐, 并含有至少一种选自药学上可接受的金属络合剂。本发明同时涉及该 组合物的制备方法及其用途。 背景技术
喹诺酮类药物现在已发展到四代, 第一代以萘啶酸为代表, 第二 代以吡哌酸为代表, 仅对革兰氏阴性菌有效, 第三代是此类药物发展 的高峰期, 出现了大量新药, 并且是广谱抗菌, 这其中以诺氟沙星, 环丙沙星等为代表。第四代喹诺酮类抗生素则是在第三代广谱的基础 上又进一步扩大了抗菌谱, 使之可对抗支原体和衣原体感染。
国内抗生素研发一直比较热门, 目前市场上应用最多的是第三代 喹诺酮类药物。 那氟沙星由日本大冢公司开发, 属于第三代喹诺酮抗 菌药, 外用治疗痤疮和毛嚢炎。 1993 年首次在曰本上市 (商品名: Acua t im ), 2004年在德国上市(商品名: Nadixa ), 2005年在中国上 市(商品名: 依尤宁, 1 %软膏)。 目前在英国和法国处于临床前研究, 在美国处于临床研究阶段。
那氟沙星由于其吸收和血管刺激性等问题, 仅能制成外用制剂, 用于体夕卜疾 丙酸杆菌 ( ropionibac ter ium acnes ) 引起的痤疾。 其中 S- (-) -那氟沙星是主要起作用的异构体, 其抗菌活性是 R型异构 体的 64 ~ 256倍, 是消旋体的 2倍。
S- (-) -那氟沙星 L-精氨酸盐是在 S- (-) -那氟沙星的基础上成盐 而制得。 显著改善了那氟沙星的溶解度以及体内吸收利用, 因此它保
留了那氟沙星抗菌谱广, 抗菌活性强, 尤其对曱氧西林敏感金黄色葡 萄球菌和曱氧西林耐药金黄色葡萄球菌有效的特点(Ant imicrob ia l Agent s and Chemotherapy, 2004, 3188 - 31920; J. Med. Chem.
2005 (48) , 5232 - 5242) 0 临床前试验证明, 本品与市场上抗曱氧西林 耐药金黄色葡萄球菌抗生素比较有更好的疗效, 包括万古霉素、 曲伐 沙星、 奎奴普丁 +达福普汀、 利奈唑胺等。
S- (-) -那氟沙星 L-精氨酸盐分子结构式如下式所示:
s- (-) -那氟沙星与精氨酸成盐后,进一步提高了起主要抗菌作用 的 s- (-) -那氟沙星异构体的含量, 并且提高了口服生物利用度, 降 低了血管刺激性, 使其能够开发为口服或注射制剂。
S- (-) -那氟沙星 L-精氨酸盐的水溶解性虽然较那氟沙星有了显 著性增加, 但是, 药物水溶液在光照下不稳定, 因此不能用简单的制 剂处方来制备其注射剂。 发明内容
本发明人意外的发现, 在 S- (-) -那氟沙星 L-精氨酸盐制剂中加 入金属络合剂, 可以显著的提高 S- (-) -那氟沙星 L-精氨酸盐溶液的 稳定性。 所制备的溶液在高温灭菌时也能保持稳定。
本发明的目的在于提供一种稳定的组合物,该组合物含有作为活 性成分的 S- (-) -那氟沙星 L-精氨酸盐, 并含有至少一种选自药学上
所述的 S- (-) -那氟沙星 L-精氨酸盐, 包括 S- (-) -那氟沙星 L- 精氨酸盐无水物、 S- (-) -那氟沙星 L-精氨酸盐一水物、 S- (-) -那氟 沙星 L-精氨酸盐四水合物以及其他各种形式存在的 S- (-) -那氟沙星 L-精氨酸盐, 其剂量均以无水物计。 S- (-) -那氟沙星 L-精氨酸盐可 依照文献方法 ( J. Med. Chem. , 2005, 48, 5232 ~ 5242 )制备得到。
所述的药物组合物, 每个剂量单位所含活性成分 S- (-) -那氟沙 星 L -精氨酸盐的量为 50 ~ 1000mg。
所述的金属络合剂 ,选自乙二胺四乙酸二钠或乙二胺四乙酸二钠 钙。
本发明人在研究过程中发现, 不加金属络合剂时, S- (-) -那氟沙 星 L-精氨酸盐药物溶液在光照条件下颜色容易发生变化, 性质不稳 定, 本发明人进一步发现, 在制剂中加入金属络合剂乙二胺四乙酸二 钠或乙二胺四乙酸二钠钙能达到良好的稳定本品的作用。
下表对比了釆用同一批次 S- (-) -那氟沙星 L-精氨酸盐 (有关物 质 99. 80 % )制备的无金属络合剂存在的 S- (-) -那氟沙星 L-精氨酸 盐溶液(样品 A、 样品 B )和有金属络合剂存在的 S- (-) -那氟沙星 L- 精氨酸盐溶液 (样品 C、 样品 D )在高温 ( 60°C )、 高湿( RH75 % )和 强光( 4000Lx ) 的条件下放置 10天后监测指标的变化:
所述的组合物, 可以注射给药, 例如可以是注射液, 或者进一 步制备成注射用冻干粉针的剂型。在本发明的注射液中或冻干粉针冷 冻干燥前的溶液中 S- (-) -那氟沙星 L-精氨酸盐的浓度为 lmg ~ 40mg/ml , 优选为 2mg - 30 mg/ml。
所述的金属络合剂中, 由于乙二胺四乙酸二钠可与钙离子结合 成可溶的络合物引起钙的减少,静脉制剂中使用乙二胺四乙酸二钠会 导致血钙下降, 因此, 需密切关注和严格控制静脉给药制剂中乙二胺 四乙酸二钠的用量。 一般药品使用的范围为 0. 01 ~ 1. 0 % , 据此, 本 发明组合物中, S- (-) -那氟沙星 L-精氨酸盐与金属络合剂的重量比 为 1 : 0. 1 ~ 1: 10。
所述的药物组合物, 按照制剂的一般要求, 还可以包括用于注 射液或注射用冻干粉针的其他药学上可接受的常规辅料。这些常规的 辅料包括但不限于冷冻干燥赋形剂、 防腐剂、 稳定剂、 pH 调节剂、 等渗剂。其中赋形剂可选自但不限于甘露醇、乳糖、 葡萄糖、 山梨醇、 氯化钠、 水解明胶、 右旋糖酐、 蔗糖、 甘氨酸、 聚乙烯吡咯烷酮等中 的一种或几种, 优选为甘露醇或葡萄糖。 防腐剂可以选自但不限于苯 酚、 曱酚、 三叔丁醇、 苯曱醇、 尼泊金中的一种或几种。 稳定剂可以 选自但不限于焦亚^ 酸钠、 代^ 酸钠、 亚^ 酸钠、 亚^ 酸氢钠、 石克 脲、 维生素 C、 叔丁基对羟基茴香醚、 二丁基苯酚、 没食子酸丙酯、 生育酚、 曱硫氨酸、 盐酸半胱氨酸、 乙酰半胱氨酸、 抗坏血酸棕榈酸 酯、 乙二胺四乙酸的一种或几种。 pH 调节剂包括但不限于盐酸、 马 来酸、 枸橼酸、 酒食酸、 磷酸、 偏磷酸、 聚偏磷酸、碳酸、 氢氧化钠、 氢氧化钾、 枸橼酸钠、 枸橼酸钾、 碳酸氢钠、 碳酸氢钾、 碳酸胺、 磷
酸氢二钠、 碑酸氢二钾、 乙醇胺、 二乙醇胺、 三乙醇胺、 碳酸钠、 酒 石酸钠钾、 偏碑酸钾中的一种或几种。 等渗剂可以选自但不限于氯化 钠、 葡萄糖、 氯化钾、 乳酸钠、 甘露醇或山梨醇。
本发明的药物组合物中, S- (-) -那氟沙星 L-精氨酸盐的用量没 有特别的限制, 可以是在注射液中通常使用的任何剂量。 一般地, 在 上述的注射剂型中, 每个制剂单位含有效成分 50 ~ 1000mg。 所说的 每个制剂单位, 是指水针或粉针的每支、 输液的每瓶等。
本发明的 S- (-) -那氟沙星 L-精氨酸盐的药用组合物可以是澄明 的可注射的水溶液形式, 或为注射用冻干粉针的形式。 可以用注射用 水、 5%葡萄糖溶液或 0. 9 %氯化钠直接溶解冻干粉针, 得到澄明的注 射液。
本发明的 S- (-) -那氟沙星 L-精氨酸盐组合物具有以下特点: 不 需要专用溶媒, 稳定性好, 便于临床使用, 刺激性小。
本发明的 S- (-) -那氟沙星 L-精氨酸盐注射液或注射用冻干粉针 适合于皮下注射、 月几内注射、 静月永注射或静月永滴注。。
另一方面, 本发明提供了一种改善 S- (-) -那氟沙星 L-精氨酸盐 稳定性的方法, 包括将(S ) -那氟沙星精氨酸盐和金属络合剂混合 于水性溶媒(水溶液、 甘露醇水溶液或含有其他任意辅料的水溶液) 的步骤, 混合后加入活性炭搅拌, 经过 0. 8 μ ηι滤膜粗滤炭后, 再用 0. 22 μ ηι滤膜除菌, 分装。 另外该方法还可以再进一步包括将上述注 射液冷冻干燥制成冻干粉针的步骤,其中冷冻干燥釆用药剂领域中冷 冻干燥注射剂的常规冻干技术,本领域技术人员根据现有技术以及教 科书中的技术教导不需要创造性劳动即可完成。
本发明的第三个方面是将本发明的 S- (-) -那氟沙星 L-精氨酸盐 组合物用于抗生素药物的制备中。所述组合物可用于治疗革兰氏阳性
菌和阴性菌导致的各种疾病, 包括脓毒血症、尿路感染、呼吸道感染。 本发明的各种改进和变化对本技术领域技术人员是显而易见的, 以下具体优选实施方式描述了本发明,但应理解要求保护的本发明不 应限制于以下具体实施方案。 具体实施方式
实施例 1
S- (-) -那氟沙星 L -精氨酸盐 5g
氯化钠 80g
甘露醇 80g
乙二胺四乙酸二钠 0. 2g
注射用水 至 1000ml
制成 100支 将 S- (-) -那氟沙星 L-精氨酸盐加入注射用水中, 然后和甘露醇 混合搅拌, 加入氯化钠和乙二胺四乙酸二钠, 混合, 溶液加入 0. 1 % 活性炭搅拌 20分钟。 溶液经过 0. 8 μ ηι滤膜粗滤脱炭后, 再用 0. 22 μ ηι滤膜除菌, 分装至西林瓶中, 灯检, 即得。 实施例 2
S- (-) -那氟沙星 L -精氨酸盐 30g
0. 1M氢氧化钠 适量
氯化钠 8g
聚维酮 3g
亚石克酸钠 4g
苯酚 1. Og
乙二胺四乙酸二钠钙 0. lg
注射用水至 1000ml
制成 100支 取 S- (-) -那氟沙星 L -精氨酸盐, 加入 50~60°C注射用水中, 以 氢氧化钠调 pH至 8.0 ~ 8.5, 加入氯化钠、 苯酚、 亚充酸氢钠和乙二 胺四乙酸二钠钙, 再补充注射用水至规定量, 溶液加入 0.1%活性炭 搅拌 20分钟。 溶液经过 0.8 μ m滤膜粗滤脱炭后, 再用 0.22 μ m滤膜 除菌, 分装至西林瓶中, 灯检, 即得。 实施例 3
S- (-) -那氟沙星 L -精氨酸盐 100g
十二烷基硫酸钠 208g
葡萄糖 2000g
0.1M氢氧化钠 适量
乙二胺四乙酸二钠 9g
注射用水至 50000ml
制成 100支 取(S) -那氟沙星精氨酸盐, 加入注射用水中, 以氢氧化钠调 pH至 7.5~ 8.0, 加入葡萄糖、 乙二胺四乙酸二钠钙, 再补充注射用 水至规定量, 溶液加入 0.1%活性炭搅拌 20分钟。 溶液经过 0.8 μηι 滤膜粗滤脱炭后, 再用 0.22 μηι滤膜除菌, 分装至输液瓶中, 灯检, 即得。
实施例 4
S- (-) -那氟沙星 L -精氨酸盐 50. Og 氯化钠 225g
乙二胺四乙酸二钠钙 5g
氢氧化钾 适量
苯曱酸钠 500 g
代 ^酸钠 l OOg
注射用水至 25000ml
制成 100支
取 S- (-) -那氟沙星 L-精氨酸盐, 加入注射用水中, 以氢氧化钾 调 pH至 7. 5 ~ 8. 0, 加入氯化钠、 苯曱酸钠、 石克代石克酸钠和乙二胺四 乙酸二钠钙, 再补充注射用水至规定量, 溶液加入 0. 1 %活性炭搅拌 20分钟。溶液经过 0. 8 μ m滤膜粗滤脱炭后,再用 0. 22 μ m滤膜除菌 , 分装至输液瓶中, 灯检, 即得。
将实施例 1和 2制得的溶液按以下方法进行冷冻干燥:
预冻: 制品温度下降至 -45 °C , 保温 3小时后即可以升华干燥; 升华干燥: 生活干燥温度控制在 -12 °C以下;
再干燥:再干燥阶段最高温度控制在 35 °C ,干燥失重应符合规定; 干燥结束后, 箱内压胶塞, 出箱锁铝盖, 成品检验合格后包装, 即得。
Claims
1. 一种稳定的 S- (-) -那氟沙星 L-精氨酸盐组合物, 含有作为活性成 分的 S- (-) -那氟沙星 L-精氨酸盐, 并含有至少一种选自金属络合 剂的药学上可接受的添加剂。
2. 权利要求 1 所述的药物组合物, 其特征在于金属络合剂选自乙二 胺四乙酸二钠或乙二胺四乙酸二钠 4丐。
3. 根据权利要求 3所述的药物组合物, 其特征在于 S- (-) -那氟沙星 L-精氨酸盐与金属络合剂的重量比为 1 : 0. 1 - 1: 10。
4. 根据权利要求 1 所述的药物组合物, 其中组合物为注射液或冻干 粉针。
5. 要求 4 所述的药物组合物, 其特征在于每个剂量单位所含活性成 分 S- (-) -那氟沙星 L-精氨酸盐的量为 50 ~ 1000mg。
6. 根据权利要求 4 所述的药物组合物, 其中组合物中还进一步包括 药学上可接受的注射剂辅料。
7. 以上任一项权利要求所述的药物组合物在制备抗生素药物中的用 途。
8. 权利要求 1 ~ 6中任一权利要求所述的药物组合物的制备方法, 包 括将 S- (-) -那氟沙星 L-精氨酸盐和金属络合剂混合于水性溶媒的 步骤。
9. 根据权利要求 8 所述的制备方法, 其中还进一步包括加入药学上 可接受的注射剂辅料, 加入活性炭、 过滤、 除菌的步骤。
10.根据权利要求 9的制备方法, 还进一步包括将所述注射液冷冻干 燥制成冻干粉针的步骤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810020691.6 | 2008-02-21 | ||
CNA2008100206916A CN101513406A (zh) | 2008-02-21 | 2008-02-21 | 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009103209A1 true WO2009103209A1 (zh) | 2009-08-27 |
Family
ID=40985054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2008/072647 WO2009103209A1 (zh) | 2008-02-21 | 2008-10-10 | 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101513406A (zh) |
WO (1) | WO2009103209A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188430B (zh) * | 2011-04-06 | 2012-08-15 | 广东如来医药进出口有限公司 | 司帕沙星化合物的组合物制剂及其制备方法 |
CN104546696A (zh) * | 2013-10-28 | 2015-04-29 | 南京长澳医药科技有限公司 | 一种s-(-)-那氟沙星-l-精氨酸单剂量滴眼液及其制备工艺 |
CN104586757A (zh) * | 2015-01-08 | 2015-05-06 | 邳州正康生物技术有限公司 | 一种兽用恩诺沙星注射液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068229A2 (en) * | 1999-05-07 | 2000-11-16 | Wockhardt Limited | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents |
WO2003099815A1 (en) * | 2002-05-28 | 2003-12-04 | Wockhardt Limited | Crystalline fluoroquinolone arginine salt form |
WO2004058303A2 (en) * | 2002-12-31 | 2004-07-15 | Wockhardt Limited | Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
-
2008
- 2008-02-21 CN CNA2008100206916A patent/CN101513406A/zh active Pending
- 2008-10-10 WO PCT/CN2008/072647 patent/WO2009103209A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000068229A2 (en) * | 1999-05-07 | 2000-11-16 | Wockhardt Limited | (s)-benzoquinolizine carboxylic acids and their use as antibacterial agents |
WO2003099815A1 (en) * | 2002-05-28 | 2003-12-04 | Wockhardt Limited | Crystalline fluoroquinolone arginine salt form |
WO2004058303A2 (en) * | 2002-12-31 | 2004-07-15 | Wockhardt Limited | Compositions of benzoquinolizine carboxylic acid antibiotic drugs |
Also Published As
Publication number | Publication date |
---|---|
CN101513406A (zh) | 2009-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5671560B2 (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
RU2647972C2 (ru) | Тетрациклиновая композиция | |
JP7229999B2 (ja) | ダプトマイシン製剤 | |
JP6832281B2 (ja) | バンコマイシンの水溶液製剤 | |
CN106659711A (zh) | 呈现长期稳定性的褪黑素注射剂的持久制剂 | |
JP2016521731A (ja) | 抗がん剤を含む安定な水溶性医薬組成物 | |
WO2019006741A1 (zh) | 一种白头翁皂苷b4的注射用制剂 | |
CN101637447B (zh) | 一种西他沙星注射剂及其制备方法 | |
IL182993A (en) | Use of enrofloxacin for production of pharmaceutical compositions for parenteral administration for the treatment of mastitis | |
WO2005004874A1 (fr) | Preparation medicinale lyophilisee stable contenant de la tetrodotoxine | |
CN102860980A (zh) | 一种罗库溴铵注射液的制备方法 | |
WO2009103209A1 (zh) | 一种稳定的s-(-)-那氟沙星l-精氨酸盐组合物、其制备方法及用途 | |
CN102688183B (zh) | 一种稳定的盐酸莫西沙星注射剂 | |
US20200261362A1 (en) | Solution Preparation for Aerosol Inhalation of Carbocisteine, and Preparation Method Therefor | |
CN103330933B (zh) | 含有米卡芬净或其盐的药物组合物 | |
CN1820749A (zh) | 注射用阿莫西林钠/盐酸氨溴索粉针的组方及其制备方法 | |
TWI732337B (zh) | 醫藥組成物及其用途 | |
TWI857310B (zh) | 酮咯酸胺丁三醇的液體組合物、其製備方法及應用 | |
WO2022241983A1 (zh) | 一种左酮咯酸的药物组合物及其制备方法 | |
CN103330932B (zh) | 一种米卡芬净或其盐的药物组合物 | |
CN117442590A (zh) | 包含紫檀芪的药物组合物及其制备方法与制药用途 | |
CN105168211B (zh) | 一种奥美拉唑钠药物组合物 | |
CN114376967A (zh) | 一种包括羟氯喹的组合物及其制备和应用 | |
WO2021249578A2 (zh) | 预防治疗哮喘或慢阻肺或过敏性疾病等的药物 | |
TW202421112A (zh) | (-)-表沒食子兒茶素沒食子酸酯類化合物的應用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08872628 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08872628 Country of ref document: EP Kind code of ref document: A1 |